IOB - Delayed Quote EUR

Merck KGaA (0O14.IL)

114.10
-3.50
(-2.98%)
At close: 4:35:14 PM GMT+1
Loading Chart for 0O14.IL
  • Previous Close 117.60
  • Open 117.15
  • Bid 112.90 x --
  • Ask 115.45 x --
  • Day's Range 113.80 - 117.65
  • 52 Week Range 110.50 - 176.85
  • Volume 475,760
  • Avg. Volume 222,341
  • Market Cap (intraday) 52.779B
  • Beta (5Y Monthly) 0.65
  • PE Ratio (TTM) 16.12
  • EPS (TTM) 7.08
  • Earnings Date Aug 7, 2025
  • Forward Dividend & Yield 2.20 (1.48%)
  • Ex-Dividend Date May 2, 2023
  • 1y Target Est --

Merck KGaA operates as a science and technology company in Germany. The company's Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company's Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

www.merckgroup.com

63,712

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 0O14.IL

View More

Performance Overview: 0O14.IL

Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

0O14.IL
16.77%
DAX P (^GDAXI)
20.54%

1-Year Return

0O14.IL
30.72%
DAX P (^GDAXI)
28.47%

3-Year Return

0O14.IL
30.57%
DAX P (^GDAXI)
71.64%

5-Year Return

0O14.IL
19.10%
DAX P (^GDAXI)
116.72%

Compare To: 0O14.IL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0O14.IL

View More

Valuation Measures

Annual
As of 5/21/2025
  • Market Cap

    51.20B

  • Enterprise Value

    58.27B

  • Trailing P/E

    18.15

  • Forward P/E

    12.66

  • PEG Ratio (5yr expected)

    1.41

  • Price/Sales (ttm)

    2.40

  • Price/Book (mrq)

    1.71

  • Enterprise Value/Revenue

    2.73

  • Enterprise Value/EBITDA

    9.64

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.95%

  • Return on Assets (ttm)

    5.98%

  • Return on Equity (ttm)

    11.71%

  • Revenue (ttm)

    22.06B

  • Net Income Avi to Common (ttm)

    3.08B

  • Diluted EPS (ttm)

    7.08

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.93B

  • Total Debt/Equity (mrq)

    41.78%

  • Levered Free Cash Flow (ttm)

    2.19B

Research Analysis: 0O14.IL

View More

Company Insights: 0O14.IL

Research Reports: 0O14.IL

View More

People Also Watch